135 related articles for article (PubMed ID: 35851543)
1. Nivolumab for pediatric malignant peritoneal mesothelioma.
Yaman Ortaköylü M; İncesoy Özdemir S; Dinçaslan H; Taçyıldız N; Ünal AE; Soydal Ç; Fitöz ÖS; Ünal E
Pediatr Blood Cancer; 2023 Feb; 70(2):e29892. PubMed ID: 35851543
[No Abstract] [Full Text] [Related]
2. Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.
Yamazoe M; Ozasa H; Kim YH
J Thorac Oncol; 2019 Nov; 14(11):e251-e253. PubMed ID: 31668324
[No Abstract] [Full Text] [Related]
3. NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
Adler AI; Slayen S; Stegenga H; Guo Y; Diaz R; Welton NJ; Westwood N; Doull I; Crawley C
Lancet Respir Med; 2022 Oct; 10(10):e92-e93. PubMed ID: 35988573
[No Abstract] [Full Text] [Related]
4. Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma.
Rizzolo A; Ah-Lan KC; Nu TNT; Alcindor T
Clin Colorectal Cancer; 2022 Dec; 21(4):371-374. PubMed ID: 36055919
[No Abstract] [Full Text] [Related]
5. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D
Clin Lung Cancer; 2021 Mar; 22(2):71-73. PubMed ID: 33358660
[No Abstract] [Full Text] [Related]
6. Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
Becker O; Beaulaton C; Masliah-Planchon J; Servois V; Watson S
Eur J Cancer; 2021 Feb; 144():386-388. PubMed ID: 33358840
[No Abstract] [Full Text] [Related]
7. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
8. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
[TBL] [Abstract][Full Text] [Related]
9. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
10. Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma.
Cancer Discov; 2017 Aug; 7(8):OF7. PubMed ID: 28592400
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
12. Relapsed malignant pleural mesothelioma: An impressive response to Nivolumab monotherapy.
Costa-Martins S; Vicente I; Valente S
Pulmonology; 2022; 28(2):142-144. PubMed ID: 34801435
[No Abstract] [Full Text] [Related]
13. A case report of peritoneal malignant mesothelioma presenting as primary ovarian mass.
Kapoor R; Kuttikat PG; Vaiphei K; Rai B; Patel FD
J Cancer Res Ther; 2015; 11(3):654. PubMed ID: 26458642
[TBL] [Abstract][Full Text] [Related]
14. Clinical Response of Primary Malignant Pericardial Mesothelioma with Peritoneal Dissemination to Nivolumab.
Fujiwara S; Kano Y; Maejima Y; Fujioka T; Tamura K; Kirimura S; Miyake S; Okamoto R
Intern Med; 2024 Feb; 63(4):513-519. PubMed ID: 37380459
[TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma clinical trial combines immunotherapy drugs.
Chatwal MS; Tanvetyanon T
Immunotherapy; 2018 Apr; 10(5):341-344. PubMed ID: 29473471
[TBL] [Abstract][Full Text] [Related]
16. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
17. [A case of malignant peritoneal mesothelioma diagnosed with laparoscopic biopsy].
Yagi Y; Maeda T; Yoshimitsu Y; Sakuma H
Gan To Kagaku Ryoho; 2014 Aug; 41(8):995-7. PubMed ID: 25132032
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for malignant peritoneal mesothelioma.
Tanaka T; Miyamoto Y; Sakai A; Fujimoto N
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
